SCHEMBL2919296

SCHEMBL2919296

O=C(O)c1c[nH]c(=O)c2c(F)cccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.59
ALB P02768 1/20 0.44
PARP1 P09874 3/20 0.43
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42
CSNK2A1 P68400 1/20 0.42
TYMS P04818 1/20 0.41
DNA2 P51530 1/20 0.41
CASP6 P55212 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
NAPRT Q6XQN6 1/20 0.41
RAB9A P51151 1/20 0.40
CYP1A2 P05177 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HRH1 P35367 1/20 0.39
CCR3 P51677 1/20 0.39
KCNH2 Q12809 1/20 0.39
KDM3B Q7LBC6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31308821 0.87 BRPF1 (0.50) KDM4EPARP1ALDH1A1HPGDRAB9A
SCHEMBL22095134 0.87 BRPF1 (0.50) KDM4EPARP1ALDH1A1HPGDRAB9A
SCHEMBL2924789 0.87 ALDH1A1 (0.44) KDM4EPARP1ALDH1A1RAB9AHRH1
SCHEMBL2914865 0.83 NR4A2 (0.54) KDM4EALDH1A1HPGDHSD17B10HRH1
SCHEMBL29914820 0.80 PARP1 (0.49) KDM4EPARP1ALDH1A1TYMSLMNA
SCHEMBL2035484 0.77 GPR84 (0.53) KDM4EALBALDH1A1HPGDCSNK2A2
SCHEMBL31308760 0.76 PARP1 (0.45) KDM4EPARP1TYMS
SCHEMBL22094181 0.76 PARP1 (0.45) KDM4EPARP1TYMS
SCHEMBL2034897 0.76 GPR84 (0.51) KDM4EALBALDH1A1CASP6CYP1A2
SCHEMBL4574088 0.76 PARP1 (0.45) PARP1TYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1478624-B1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2010-09-08 EP disclosed
EP-1478624-B1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2010-09-08 EP disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 US disclosed
CN-100564358-C The method of a kind of preparation 4-(3, the 4-dichlorophenoxy) piperidines ASTRAZENECA AB (SE) 2009-12-02 CN disclosed
CN-100352807-C substituted piperidine compounds ASTRAZENECA AB (SE) 2007-12-05 CN disclosed
CN-1907968-A Method for making 4-(3,4-dichlorophenoxy)piperidine ASTRAZENECA AB (SE) 2007-02-07 CN disclosed
CN-1633414-A Compound (I) ASTRAZENECA AB (SE) 2005-06-29 CN disclosed
US-20050107428-A1 Chemical compounds ASTRAZENECA AB (SE) 2005-05-19 US disclosed
EP-1478624-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2004-11-24 EP disclosed
WO-2003068743-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107428-A1 Chemical compounds CCR10, CCR3, CXCR5 KDM4E 1685/4885ALB 4862/4885PARP1 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.